Hybrid Arch Aneurysm Repair With Ascending Aortic Wrap and TEVAR.

Shazly OE, Porez F, Ramadan R, Le Houérou T, Gaudin A, Costanzo A, Fabre D, Guihaire J, Haulon S

Establishment of a replacement batch for the Ph. Eur. Heparin low-molecular-mass for calibration CRS.

Costanzo A, Hogwood J

Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management.

Paolino G, Valenti M, Carugno A, Bianco M, Didona D, Di Nicola MR, Acutis PL, Cantisani C, Bianchi VG, Zerbinati N, Narcisi A, Costanzo A, Mercuri SR

Italian Expert Opinion on Chronic Hand Eczema: from Guidelines to Clinical Practice.

Stingeni L, Fargnoli MC, Guarneri F, Balato A, Corazza M, Fortina AB, Pinton PC, Costanzo A, Ferrucci SM, Naldi L, Pellacani G, Peris K, Prignano F, Girolomoni G

Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.

Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A

A New Catalogue and Insights into the 2022 Adriatic Offshore Seismic Sequence Using a Machine Learning-Based Procedure.

Costanzo A

Anxiety and Depression and Sleep Problems Among Patients with Fetal Alcohol Spectrum Disorders.

Dyląg KA, Wieczorek-Stawińska W, Cichoń-Chojnacka A, Piaskowska A, Jaroszewska K, Wasiak K, Jagła T, Frączek J, Abram A, Costanzo A, Landri F, Dumnicka P, Popiołek L

Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).

Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K

Protocol for oil red O staining of low-density lipoproteins for in vivo cell treatment.

Bini S, Covino S, Minicocci I, D'Erasmo L, Tramontano D, Di Costanzo A, Arca M, Pecce V

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study.

Gargiulo L, Ibba L, Bianco M, Di Giulio S, Alfano A, Cascio Ingurgio R, Facheris P, Perugini C, Valenti M, Costanzo A, Narcisi A